Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$22.73
+0.3%
$20.78
$10.14
$28.42
$285.19M0.8680,464 shs16,450 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$5.58
+3.3%
$5.90
$4.58
$11.64
$279.76M1.92540,723 shs97,402 shs
Inventiva S.A. stock logo
IVA
Inventiva
$3.48
+2.7%
$3.34
$1.53
$4.05
$332.90M0.864,067 shs199,686 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.27
+4.1%
$1.07
$0.83
$5.39
$78.67M1.15739,072 shs178,735 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
+2.77%-6.63%+4.52%-2.12%+78.64%
Cryoport, Inc. stock logo
CYRX
Cryoport
-10.89%-10.60%-7.85%+6.72%-47.47%
Inventiva S.A. stock logo
IVA
Inventiva
+8.27%+8.48%+0.30%+20.21%-7.63%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
+0.83%-0.81%-3.17%+7.02%-67.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4.3099 of 5 stars
4.63.00.04.62.10.80.0
Cryoport, Inc. stock logo
CYRX
Cryoport
3.0266 of 5 stars
4.41.00.00.02.72.50.6
Inventiva S.A. stock logo
IVA
Inventiva
2.3737 of 5 stars
3.43.00.00.02.11.70.6
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
1.7599 of 5 stars
3.41.00.00.02.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.22
Buy$41.8684.15% Upside
Cryoport, Inc. stock logo
CYRX
Cryoport
2.71
Moderate Buy$11.0097.13% Upside
Inventiva S.A. stock logo
IVA
Inventiva
2.80
Moderate Buy$10.40198.85% Upside
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.80
Moderate Buy$9.00608.66% Upside

Current Analyst Ratings Breakdown

Latest PYXS, CDTX, CYRX, and IVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$47.00
5/27/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$47.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $35.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
5/19/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/16/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$35.00 ➝ $50.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$33.00 ➝ $35.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $47.00
5/8/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/29/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.00
(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$302K944.35N/AN/A($1.82) per share-12.49
Cryoport, Inc. stock logo
CYRX
Cryoport
$232.13M1.21$0.33 per share16.95$9.45 per share0.59
Inventiva S.A. stock logo
IVA
Inventiva
$9.20M36.19N/AN/A($0.67) per share-5.19
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M4.87N/AN/A$2.81 per share0.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$22.93M-$29.47N/AN/AN/A-289.05%-69.64%-33.73%8/12/2025 (Estimated)
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.34N/AN/AN/A-70.08%-13.35%-6.43%8/5/2025 (Estimated)
Inventiva S.A. stock logo
IVA
Inventiva
-$119.51MN/A0.00N/AN/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$73.79M-$1.59N/AN/AN/AN/A-36.22%-28.76%8/13/2025 (Estimated)

Latest PYXS, CDTX, CYRX, and IVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.29-$0.35-$0.06-$0.35N/AN/A
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45-$1.66+$3.79-$1.66N/AN/A
5/7/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
3/18/2025Q4 2024
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.33-$0.32+$0.01-$0.60N/A$16.15 million
3/6/2025Q4 2024
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.28-$5.38-$0.10-$5.37N/AN/A
3/4/2025Q4 2024
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.33-$0.42-$0.09-$0.42$58.71 million$59.53 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
Inventiva S.A. stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.54
3.54
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
Inventiva S.A. stock logo
IVA
Inventiva
N/A
0.59
0.59
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
7.33
7.33

Institutional Ownership

CompanyInstitutional Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
Inventiva S.A. stock logo
IVA
Inventiva
19.06%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%

Insider Ownership

CompanyInsider Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.89%
Cryoport, Inc. stock logo
CYRX
Cryoport
10.00%
Inventiva S.A. stock logo
IVA
Inventiva
32.00%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
10.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9012.55 million6.51 millionNo Data
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02050.14 million44.44 millionOptionable
Inventiva S.A. stock logo
IVA
Inventiva
10095.66 million35.68 millionNot Optionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6061.95 million53.64 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$22.73 +0.06 (+0.26%)
As of 11:05 AM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cryoport stock logo

Cryoport NASDAQ:CYRX

$5.58 +0.18 (+3.33%)
As of 11:07 AM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Inventiva stock logo

Inventiva NASDAQ:IVA

$3.48 +0.09 (+2.65%)
As of 10:55 AM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.27 +0.05 (+4.10%)
As of 11:09 AM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.